Cidoteston Uses

Rating: 5 - 2 review(s)
sponsored
What is the dose of your medication?

What is Cidoteston?

Cidoteston injection is used for the treatment of men whose bodies do not make enough natural Cidoteston, a condition called hypogonadism. Cidoteston is a male hormone responsible for the growth and development of the male sex organs and maintenance of secondary sex characteristics.

Cidoteston injection is also used in women with breast cancer that has spread to other parts of the body (metastatic).

Cidoteston injection is also used to stimulate delayed puberty in male teenagers.

This medicine is to be given only by or under the direct supervision of your doctor. The Cidoteston® brand is only available under a restricted distribution program called the Cidoteston® REMS program.

Cidoteston indications

infoAn indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
sponsored

Males

Cidoteston® (Cidoteston Enanthate Injection, USP) is indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous Cidoteston.

Primary hypogonadism (congenital or acquired) – Testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, or orchidectomy.

Hypogonadotropic hypogonadism (congenital or acquired) – Gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.)

If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop Cidoteston deficiency after puberty.

Safety and efficacy of Cidoteston in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established.

Delayed puberty – Cidoteston® (Cidoteston Enanthate Injection, USP) may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every six months to assess the effect of treatment on the epiphyseal centers.

Females

Metastatic mammary cancer – Cidoteston® (Cidoteston Enanthate Injection, USP) may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are one to five years postmenopausal. Primary goals of therapy in these women include ablation of the ovaries. Other methods of counteracting estrogen activity are adrenalectomy, hypophysectomy, and/or antiestrogen therapy. This treatment has also been used in premenopausal women with breast cancer who have benefited from oophorectomy and are considered to have a hormone-responsive tumor. Judgment concerning androgen therapy should be made by an oncologist with expertise in this field.

How should I use Cidoteston?

Use Cidoteston solution as directed by your doctor. Check the label on the medicine for exact dosing instructions.

  • Cidoteston solution comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Cidoteston solution refilled.
  • Prime this product before the first use. To prime it, depress the pump 3 times and wash any product that is dispensed down the sink.
  • Depress the pump once to fill the applicator cup. Holding the applicator upright, wipe Cidoteston solution steadily up and down onto clean, dry skin in the armpit. If Cidoteston solution drips or runs, it can be wiped back up with the applicator cup. Do NOT apply Cidoteston solution to other parts of your body (eg, scrotum, penis, stomach, shoulders, upper arms). Do NOT apply it over open sores, wounds, or irritated skin.
  • Do NOT use your fingers or hand to rub the medicine into the skin.
  • You may need to alternate between armpits when applying Cidoteston solution. Be sure you understand how to apply Cidoteston solution. Contact your doctor or pharmacist if you have questions or concerns about how to apply Cidoteston solution.
  • Wash your hands with soap and water immediately after using Cidoteston solution.
  • Allow Cidoteston solution to dry completely before dressing.
  • After Cidoteston solution has dried, cover the application site (eg, with a shirt) to prevent others from coming into contact with Cidoteston solution. If direct skin-to-skin contact with another person is expected, wash the application site well with soap and water to remove the medicine.
  • After using Cidoteston solution, rinse the applicator with room temperature water and pat it dry with a tissue. Replace the applicator and cap on the bottle for storage.
  • Do NOT get Cidoteston solution in your eyes. If you do, rinse thoroughly with water. If eye irritation persists, contact your doctor.
  • Apply Cidoteston solution at the same time every morning after showering or bathing, unless your doctor tells you otherwise.
  • If you are also using an antiperspirant or deodorant (stick or roll-on), apply it at least 2 minutes before you apply Cidoteston solution.
  • For best results, wait 2 hours after applying Cidoteston solution before you wash the application site or swim.
  • If you miss a dose of Cidoteston solution, use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.

Ask your health care provider any questions you may have about how to use Cidoteston solution.

Uses of Cidoteston in details

infoThere are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
sponsored

This medication is used by men who do not make enough of a natural substance called Cidoteston (hypogonadism). Cidoteston belongs to a class of drugs known as androgens. Cidoteston helps the body to develop and maintain male sexual characteristics (masculinity), such as a deep voice and body hair. It also helps to maintain muscle and prevent bone loss, and is necessary for natural sexual ability/desire.

This drug should not be used by women.

How to use Cidoteston nasal

Read the Patient Information Leaflet if available from your pharmacist before you start using Cidoteston and each time you get a refill. Follow the illustrated directions for the proper use of this medication. If you have any questions, ask your doctor or pharmacist.

Gently blow your nose before using this medication. Follow the instructions on how to properly prime the bottle if you are using it for the first time.

Use this medication in the nose as directed by your doctor, usually 3 times a day (6 to 8 hours apart). After applying the medication into both nostrils, gently squeeze your nostrils together and lightly massage. Do not apply this medication to other areas of your body. If another part of your body comes in contact with this medication, wash the area with warm water and soap.

Do not blow your nose or sniff for 1 hour after using this medication. Wipe the tip of the applicator with a clean, dry tissue after each use.

Use this medication regularly to get the most benefit from it. To help you remember, use it at the same times each day. Do not increase your dose or use this drug more often or for longer than prescribed. Your condition will not improve any faster, and your risk of side effects will increase.

Since this drug can be absorbed through the skin and may harm an unborn baby, women who are pregnant or who may become pregnant should not handle this medication.

Tell your doctor if your condition does not improve or if it worsens.

Cidoteston description

sponsored

Cidoteston is a steroid sex hormone found in both men and women. In men, Cidoteston is produced primarily by the Leydig (interstitial) cells of the testes when stimulated by luteinizing hormone (LH). It functions to stimulate spermatogenesis, promote physical and functional maturation of spermatozoa, maintain accessory organs of the male reproductive tract, support development of secondary sexual characteristics, stimulate growth and metabolism throughout the body and influence brain development by stimulating sexual behaviors and sexual drive. In women, Cidoteston is produced by the ovaries (25%), adrenals (25%) and via peripheral conversion from androstenedione (50%). Testerone in women functions to maintain libido and general wellbeing. Cidoteston exerts a negative feedback mechanism on pituitary release of LH and follicle-stimulating hormone (FSH). Cidoteston may be further converted to dihydrotestosterone or estradiol depending on the tissue.

Cidoteston dosage

Cidoteston (Cidoteston (transdermal)) TTS

One system is applied at about the same time each day. The adhesive side of the Cidoteston (Cidoteston (transdermal)) TTS system should be placed on a clean, dry area of skin on the arm, back or upper buttocks immediately upon removal from the protective pouch. DO NOT APPLY TO THE SCROTUM. The area selected should not be oily, damaged, or irritated. The system should be pressed firmly in place with the palm of the hand for about 10 seconds, making sure there is good contact, especially around the edges. In the event that a system should fall off, the same system may be reapplied. If the system comes off after it has been worn for more than 12 hours and it cannot be reapplied, a new system may be applied at the next routine application time. In either case, the daily treatment schedule should be continued. The Cidoteston (Cidoteston (transdermal)) TTS system should be worn approximately 24 hours and then replaced. To ensure proper dosing, serum Cidoteston concentration may be measured 2-4 hours after an application of Cidoteston (Cidoteston (transdermal)) TTS. If the serum Cidoteston concentrations are low, the dosing regimen may be increased to 2 systems. Because of variability in analytical values among diagnostic laboratories, all Cidoteston measurements should be performed at the same laboratory.

Cidoteston (Cidoteston (transdermal)) and Cidoteston (Cidoteston (transdermal)) WITH ADHESIVE

Patients should start therapy with a 6 mg/d system of either Cidoteston (Cidoteston (transdermal)) or Cidoteston (Cidoteston (transdermal)) WITH ADHESIVE applied daily; if the scrotal area cannot accommodate a 6 mg/d system, a 4 mg/d Cidoteston (Cidoteston (transdermal)) system should be used. One Cidoteston (Cidoteston (transdermal)) or Cidoteston (Cidoteston (transdermal)) WITH ADHESIVE system should be placed on clean, dry, scrotal skin. Scrotal hair should be dry-shaved for optimal skin contact. Chemical depilatories should not be used. Cidoteston (Cidoteston (transdermal)) or Cidoteston (Cidoteston (transdermal)) WITH ADHESIVE should be worn 22-24 hours.

After 3-4 weeks of daily system use, blood should be drawn 2-4 hours after system application for determination of serum total Cidoteston. Because of variability in analytical values among diagnostic laboratories, this laboratory work and later analyses for assessing the effect of the Cidoteston (Cidoteston (transdermal)) and Cidoteston (Cidoteston (transdermal)) WITH ADHESIVE therapy should be performed at the same laboratory.

If patients have not achieved desired results by the end of 6-8 weeks of treatment with any of the Cidoteston (Cidoteston (transdermal)) products, another form of Cidoteston replacement therapy should be considered.

How supplied

Cidoteston (Cidoteston (transdermal)) TTS, Cidoteston (Cidoteston (transdermal)), and Cidoteston (Cidoteston (transdermal)) WITH ADHESIVE Cidoteston transdermal systems contain a Schedule III controlled substance as defined by the Anabolic Steroids Control Act.

Cidoteston (Cidoteston (transdermal)) TTS

Cidoteston (Cidoteston (transdermal)) TTS systems are supplied as individually pouched systems, 30 per carton. Cidoteston (Cidoteston (transdermal)) TTS 5 mg/d (Cidoteston Transdermal System) -- each 60 cm2 system contains 328 mg Cidoteston USP for nominal dose of 5 mg/day

Carton of 30 Cidoteston (Cidoteston (transdermal)) TTS 5 mg/d systemsNDC 17314-4717-3

Cidoteston (Cidoteston (transdermal)) and Cidoteston (Cidoteston (transdermal)) WITH ADHESIVE

Cidoteston (Cidoteston (transdermal)) and Cidoteston (Cidoteston (transdermal)) WITH ADHESIVE systems are supplied as individually pouched systems, 30 per carton.

Cidoteston (Cidoteston (transdermal)) 4 mg/d (Cidoteston Transdermal System) -- each 40 cm2 system contains 10 mg Cidoteston USP for nominal delivery of 4 mg for one day.

Carton of 30 Cidoteston (Cidoteston (transdermal)) 4 mg/d systems. NDC 17314-4608-3

Cidoteston (Cidoteston (transdermal)) and Cidoteston (Cidoteston (transdermal)) WITH ADHESIVE

6 mg/d (Cidoteston Transdermal System) -- each 60 cm2 system contains 15 mg Cidoteston USP for nominal delivery of 6 mg for one day.

Carton of 30 Cidoteston (Cidoteston (transdermal)) 6 mg/d systems. NDC 17314-4609-3

Carton of 30 Cidoteston (Cidoteston (transdermal)) WITH ADHESIVE 6 mg/d systemsNDC 17314-2836-3

Storage

Cidoteston (Cidoteston (transdermal)) TTS

Store at controlled room temperature below 25oC (77oF).

Cidoteston (Cidoteston (transdermal)) and Cidoteston (Cidoteston (transdermal)) WITH ADHESIVE

Store at room temperature 15-30oC (59-86oF).

Disposal

Cidoteston (Cidoteston (transdermal)) products should be discarded in household trash in a manner that prevents accidental application or ingestion by children or pets.

Caution: Federal law prohibits dispensing without prescription.

REFERENCE

1. Matsumoto AM, Sandblom RE, Schoene RB et al. Cidoteston replacement in hypogonadal men: Effects on obstructive sleep apnoea, respiratory drives, and sleep. Clin Endocrinol (1985) 22: 713-721.

2. Schneider BK, Pickett CK, Zwillich CW et al. Influence of Cidoteston on breathing during sleep. J Appl Physiol (1986) 61: 618-623.

3. Matsumoto AM. Hormonal therapy of male hypogonadism. Endocrinol Metab Clin North Am. (1994) 23: 857-875.

4. Bardin CW, Swerdloff RS, Santen RJ. Androgens: Risks and benefits. J Clin Endocinol Metab (1991) 73: 4-7.

5. Nieschlag E, Wang CCL. Guidelines for the use of androgens in men. Geneva: World Health Organization (1992); 1-16.

6. Walle T, Walle UK, Mathur RS et al. Propranolol metabolism in normal subjects: Association with sex steroid hormones. Curr Pharmacol Ther (1994) 56:127-132.

7. Physicians Generic Rx: The Complete Drug Reference. (1996); II-1972

Cidoteston interactions

See also:
What other drugs will affect Cidoteston?

sponsored

Drug Interactions

Anticoagulants: C-17 substituted derivatives of Cidoteston, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. Patients receiving oral anticoagulant therapy require close monitoring, especially when androgens are started or stopped.

Oxyphenbutazone: Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.

Insulin: In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore, insulin requirements.

Propranolol: In a published pharmacokinetic study of an injectable Cidoteston product, administration of Cidoteston cypionate led to an increased clearance of propranolol in the majority of men tested.6

Corticosteroids: The concurrent administration of Cidoteston with ACTH or corticosteroids may enhance edema formation; thus these drugs should be administered cautiously, particularly in patients with cardiac or hepatic disease.7

Drug/Laboratory Test Interactions

Androgens may decrease levels of thyroxin-binding globulin, resulting in decreased total T. Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction.

The Cidoteston (Cidoteston (transdermal)) products contain a Schedule III controlled substance as defined by the Anabolic Steroids Control Act.

Cidoteston (Cidoteston (transdermal)) TTS is designed for application to arm, back or upper buttocks skin.

Cidoteston (Cidoteston (transdermal)) and Cidoteston (Cidoteston (transdermal)) WITH ADHESIVE are designed for application to scrotal skin only. Because scrotal skin is at least five times more permeable to Cidoteston than other skin sites, Cidoteston (Cidoteston (transdermal)) or Cidoteston (Cidoteston (transdermal)) WITH ADHESIVE will not produce adequate serum Cidoteston concentrations if applied to non-scrotal skin.

Ingestion of Cidoteston, or the contents of any of the Cidoteston (Cidoteston (transdermal)) products will not result in clinically significant serum Cidoteston concentrations due to extensive first-pass metabolism. In addition, an intramuscular injection of Cidoteston from any of the Cidoteston (Cidoteston (transdermal)) products will not produce adequate serum Cidoteston levels due to its short half-life (about 10 minutes).

Cidoteston side effects

See also:
What are the possible side effects of Cidoteston?

Adverse events are reported in this section by product. Adverse events reported during use of a given product may occur in patients who are treated with any Cidoteston (Cidoteston (transdermal)) product.

Adverse Events with Cidoteston (Cidoteston (transdermal)) TTS

In clinical studies of 457 participants (116 hypogonadal males and 341 healthy adult males) treated for up to 6 weeks with Cidoteston (Cidoteston (transdermal)) TTS, the most commonly reported adverse events were application site reactions of transient itching (12%) and moderate or severe erythema (3%).

Adverse events reported by less than 1% of Cidoteston (Cidoteston (transdermal)) TTS users in clinical trials that were of probable or unknown relationship to drug were:

Body as a Whole: abdominal pain, back pain, infection;
Cardiovascular System: congestive heart failure, hypertension, tachycardia;
Digestive System: diarrhea, nausea;
Metabolic and Nutritional System: hyperglycemia, hyperlipemia, hyponatremia;
Musculoskeletal System: arthralgia;
Nervous System: nervousness, depression, dizziness, dry mouth, insomnia, decreased libido, personality disorder, CNS stimulation;
Respiratory System: bronchitis;
Skin System: application site reactions--papules/pustules, edema, vesicles, pain, other--, acne, alopecia, hirsutism;
Urogenital System: abnormal ejaculation, breast pain, dysuria, urinary tract infection, and impaired urination.

Topical Reactions

Of 457 study participants, 3 men (1%) discontinued prematurely because of application site reactions.

There were no clinically significant differences in skin tolerability in younger (<65 years old) and older (³ 65 years old) subjects.

A contact sensitization rate of 0.5% for Cidoteston (Cidoteston (transdermal)) TTS was observed in a 6-week study of 233 normal male volunteers.

In one study with 14 days of daily use, 42% of patients reported 3 or more detachments of their Cidoteston (Cidoteston (transdermal)) TTS; of these detachments, 33% occurred during exercise.

Adverse Events with Cidoteston (Cidoteston (transdermal))

In clinical studies of 104 patients treated with Cidoteston (Cidoteston (transdermal)), the most common adverse effects reported were local effects. In US clinical trials, most of the 72 patients filling out a daily questionnaire reported scrotal itching, discomfort, or irritation at some time during therapy. Of all the daily questionnaire responses, 7% reported itching, 4% discomfort, and 2% irritation. All topical reactions decreased with duration of use.

The following adverse effects (greater than 1%) were reported in association with Cidoteston (Cidoteston (transdermal)) therapy in 104 patients using the product for up to three years. These effects are listed in decreasing frequency of occurrence with the percentages of patients reporting the effect in parentheses: Gynecomastia (5%), acne (4%), prostatitis/urinary tract infection (4%), breast tenderness (3%), stroke (2%). For this same patient population, the following adverse effects were reported by 1% of users: memory loss, pupillary dilation, abnormal liver enzymes, scrotal cellulitis, deep vein phlebitis, benign prostatic hyperplasia, rectal mucosal lesion over prostate, hematuria/bladder cancer, papilloma on scrotum, and congestive heart failure.

Adverse Events with Cidoteston (Cidoteston (transdermal)) WITH ADHESIVE

In a pharmacokinetic study in 50 normal men, skin assessment scores following a single 24-hour application of Cidoteston (Cidoteston (transdermal)) WITH ADHESIVE to scrotal skin were similar to those for Cidoteston (Cidoteston (transdermal)). Other adverse events reported during the study were headache (6%), dizziness (6%), back pain, pain, nausea, and pustular rash (1% each).

General Adverse Events with Androgen Replacement Therapy

Skin and Appendages: Hirsutism, male pattern baldness, seborrhea, and acne.

Endocrine and Urogenital: Gynecomastia and excessive frequency and duration of penile erections. Oligospermia may occur at high doses.

Fluid and Electrolyte Disturbances: Retention of sodium, chloride, water, potassium, calcium, and inorganic phosphates.

Gastrointestinal: Nausea, cholestatic jaundice, alterations in liver function tests. Rare instances of hepatocellular neoplasms and peliosis hepatis have occurred.

Hematologic: Suppression of clotting factors II, V, VII, and X, bleeding in patients on concomitant anticoagulant therapy, and polycythemia.

Nervous System: Increased or decreased libido, headache, anxiety, depression, and generalized paresthesia.

Metabolic: Increased serum cholesterol.

Miscellaneous: Rarely, anaphylactoid reactions.

DRUG ABUSE AND DEPENDENCE

The Cidoteston (Cidoteston (transdermal)) products contain a Schedule III controlled substance as defined by the Anabolic Steroids Control Act.

Cidoteston (Cidoteston (transdermal)) TTS is designed for application to arm, back or upper buttocks skin.

Cidoteston (Cidoteston (transdermal)) and Cidoteston (Cidoteston (transdermal)) WITH ADHESIVE are designed for application to scrotal skin only. Because scrotal skin is at least five times more permeable to Cidoteston than other skin sites, Cidoteston (Cidoteston (transdermal)) or Cidoteston (Cidoteston (transdermal)) WITH ADHESIVE will not produce adequate serum Cidoteston concentrations if applied to non-scrotal skin.

Ingestion of Cidoteston, or the contents of any of the Cidoteston (Cidoteston (transdermal)) products will not result in clinically significant serum Cidoteston concentrations due to extensive first-pass metabolism. In addition, an intramuscular injection of Cidoteston from any of the Cidoteston (Cidoteston (transdermal)) products will not produce adequate serum Cidoteston levels due to its short half-life (about 10 minutes).

Cidoteston contraindications

See also:
What is the most important information I should know about Cidoteston?

  • Cidoteston 1% is contraindicated in men with carcinoma of the breast or known or suspected carcinoma of the prostate.
  • Cidoteston 1% is contraindicated in women who are or may become pregnant, or who are breastfeeding. Cidoteston 1% may cause fetal harm when administered to a pregnant woman. Cidoteston 1% may cause serious adverse reactions in nursing infants. Exposure of a female fetus or nursing infant to androgens may result in varying degrees of virilization. Pregnant women or those who may become pregnant need to be aware of the potential for transfer of Cidoteston from men treated with Cidoteston 1%. If a pregnant woman is exposed to Cidoteston 1%, she should be apprised of the potential hazard to the fetus.

Active ingredient matches for Cidoteston:

Testosterone in Egypt.


List of Cidoteston substitutes (brand and generic names)

Sort by popularity
Unit description / dosage (Manufacturer)Price, USD
Cernos 40mg Soft Gelatin Capsule (Sun Pharmaceutical Industries Ltd.)$ 2.21
Cypionax 200 mg/2 mL x 10's
Injectable; Injection; Testosterone Enanthate 200 mg / ml
Delatestryl solution 200 mg (Valeant Canada Lp Valeant Canada S.E.C. (Canada))
Delatestryl injection, solution 200 mg/mL (Endo Pharmaceuticals Solutions Inc. (US))
Depo-Testomon 100 mg/1 mL x 2 mL
Injectable; Injection; Testosterone Cypionate 100 mg / ml (Pfizer)
Injectable; Injection; Testosterone Cypionate 200 mg / ml (Pfizer)
Injectable; Injection; Testosterone Cypionate 50 mg / ml (Pfizer)
Depo-Testosterone / vial 100 mg/1 mL x 10 mL x 1's (Pfizer)
Depo-Testosterone / vial 200 mg/1 mL x 1 mL x 1's (Pfizer)
1 milliliter in 1 vial (Pfizer)
10 milliliter in 1 vial (Pfizer)
Depo-Testosterone inj 100 mg/mL / vial 10 mL x 1's (Pfizer)
Depo-Testosterone inj 200 mg/mL / vial 1 mL x 1's (Pfizer)
Depo-testosterone injection, solution 100 mg/mL (Pfizer)
Depo-testosterone injection, solution 200 mg/mL (Pfizer)
Fortesta gel, metered 10 mg/.5g (Endo Pharmaceuticals Inc. (US))
Gel; Topical; Testosterone 2%

References

  1. DailyMed. "TESTOSTERONE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  2. PubChem. "testosterone". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
  3. DrugBank. "testosterone". http://www.drugbank.ca/drugs/DB00624 (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Cidoteston are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Cidoteston. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

1 consumer reported useful

Was the Cidoteston drug useful in terms of decreasing the symptom or the disease?
According to the reports released by ndrugs.com website users, the below mentioned percentages of users say the drug is useful / not useful to them in decreasing their symptoms/disease. The usefulness of the drug depends on many factors, like severity of the disease, perception of symptom, or disease by the patient, brand name used [matters only to a certain extent], other associated conditions of the patient. If the drug is not effective or useful in your case, you need to meet the doctor to get re-evaluated about your symptoms/disease, and he will prescribe an alternative drug.
Users%
Useful1
100.0%


Consumer reported price estimates

No survey data has been collected yet


Consumer reported time for results

No survey data has been collected yet


1 consumer reported age

Users%
16-291
100.0%


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 13 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2019 ndrugs.com All Rights Reserved